 Dividend.com | Abbott Beats, Raises Outlook Zacks.com Abbott Labs, along with partner Biogen (BIIB), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease ... Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter ... |
